Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elagolix in Endometriosis-Associated Pain (ELARIS EM-II)
NCT01931670Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2013
- Primary completion
- Jan 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of elagolix in endometriosis (3 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Responders Based on Daily Assessment of Dysmenorrhea at 3 months and Percentage of Responders Based on Daily Assessment of Non-Menstrual Pelvic Pain at 3 months. Started Sep 2013; status: completed.
02
Drugs
elagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT01931670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931670.